- Home
- News
- latamerica
- oral cancer
Oral Cancer Articles & Analysis
15 news found
In this trial, patients received LYTGOBI orally once daily at a dose of 20mg until disease progression or unacceptable toxicity. ...
About trifluridine and tipiracil Trifluridine and tipiracil is an oral nucleoside antitumor agent discovered and developed by Taiho Pharmaceutical Co., Ltd. ...
From relatively simple tasks like removing impacted teeth to life-saving measures like removing oral cancer, these highly skilled professionals are trained to rescue their patients in their time of need. ...
These data were presented as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ...
EDT Session title: Harnessing Innate Immunity for Cancer Immunotherapy Oral presentation time: 4:45 – 5:00 p.m. EDT Abstract: #844 Multi-Arming and Regulator Dial Gene Circuits to Address Key Disease Challenges in HCC, Guzman et al. Session date/time: May 16, 5:30 - 6:30 p.m. EDT Session title: Cancer - Targeted Gene and Cell ...
The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer. ...
Futibatinib is an investigational, oral, potent, selective and irreversible small-molecule inhibitor ofFGFR1, 2, 3 and 4. ...
Raise in peak sales expectations follows presentation of positive Phase III trial ARASENS with darolutamide (Nubeqa) in metastatic hormone-sensitive prostate cancer at 2022 ASCO GU Cancers Symposium and publication in The New England Journal of Medicine on February 17, 2022 Broad development program underway with three additional ongoing or planned large ...
ByBayer AG
Results from the Phase III ARASENS trial evaluating darolutamide plus androgen deprivation therapy (ADT) and docetaxel showed a statistically significant increase in overall survival with a reduction in the risk of death by 32.5% compared to ADT plus docetaxel (HR=0.68, 95% CI 0.57-0.80; P Consistent benefits were also seen across secondary endpoints, which are of key relevance to patients, ...
ByBayer AG
Lab technicians and data entry operators appointed by the Foundation are providing services for RT-PCR reporting, phone monitoring of quarantined patients and vaccination data entry, in 20 Government Primary Health Care Centers. The Oral Cancer mHealth program developed by the Foundation to address a critical need for cancer screening in India ...
ByBiocon
Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with the daily oral chemotherapy candidate drug Oncoral. “We are very happy that the FDA has accepted our IND application to start our Phase 2 study with Oncoral in the US, which ...
The REBORN©1 trial is a head-to-head, open-label, crossover phase 2 study against oral opioids in the management of short and frequent episodes of incapacitating pain (breakthrough pain) in patients with cancer. ...
The REBORN1© trial is a head-to-head phase 2 study against an opioid treatment in the management of short and frequent episodes of incapacitating pain (breakthrough pain) requesting immediate release opioid treatment in patients living with cancer. The initial protocol was assessing a direct safety and efficacy comparison between QIXLEEF™ and oral ...
The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF (trifluridine and tipiracil) film-coated tablets for oral use. ...
Oral cancer is part of a group of cancers commonly referred to as head and neck cancers. According to the National Center for Biotechnology Information, under the U.S. National Institutes of Health, oral cancer is the sixth most common cancer worldwide. Over 275,000 new cases are ...